TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Imaging Characteristics of a Follow-up 18F-AV-1451 Scan

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a previous 18F-AV-1451 brain scan~* Can tolerate up to two Positron Emission Tomography (PET) imaging sessions and a Magnetic Resonance Imaging (MRI) scan~* Ability to provide informed consent~Exclusion Criteria:~* Current clinically significant psychiatric disease~* Are claustrophobic~* Current clinically significant cardiovascular disease or ECG abnormalities, or additional risk factors for Torsades de Pointes~* Current clinically significant infectious disease, endocrine or metabolic disease, pulmonary, renal or hepatic impairment, or cancer~* Females of childbearing potential who are not surgically sterile, not refraining from sexual activity or not using reliable methods of contraception~* Have had a non-study related radiopharmaceutical imaging or treatment procedure within 7 days prior to the study imaging session

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- Follow-up Flortaucipir PET Scan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Study of Parenteral Nutrition to Patients With Gastrointestinal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically confirmed non-resectable GI-Cancer~* at nutritional risk; having lost 5% of body weight during the previous 3 months or has failed to reach intake by 25% in the last 2 weeks.~* At performance status 0-2~* Life expectancy more than 3 months.~* Age over 18 years old.~* Able to give written consent~Exclusion Criteria:~* Gastrointestinal obstruction or failure.~* Immune deficiency diseases (apart from the cancer disease. )~* Current infection or sepsis.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Best nutritional Care (Type: ACTIVE_COMPARATOR): Best supportive nutritional care and dietician advise
- Parenteral nutrition (Type: EXPERIMENTAL): Supplemental Parenteral Nutrition and dietician advise. Supplemental parenteral Nutrition 30% of estimated needs. Parenteral nutrition given at home, administered by a nurse. The patient will be seen at the Outpatient Clinic every 6th week, talk to dietician and a doctor.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Oral Screens in Post Stroke Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* First or second stroke 8-12 months earlier.~* Remaining subjective and objective swallowing difficulties.~* Can eat. Can perform the training by himself/herself or with assistance from someone.~* Natural teeth corresponding category A according to Eichner's index~Exclusion Criteria:~* Moderate to severe impressive aphasia: \<4.0 points by A-ning~* Moderate to severe cognitive impairment: \<23 by MoCA~* Unilateral neglect according to baking tray task

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Intervention (Type: EXPERIMENTAL): Oral screen
- Control (Type: NO_INTERVENTION): No intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparison of Continuous Non-Invasive and Invasive Intracranial Pressure Measurement

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of suspected symptomatic hydrocephalus or idiopathic intracranial hypertension (pseudotumor cerebri)~* ICP monitoring via 25-ga needle in an existing shunt reservoir or ICP monitoring via spinal catheter has been recommended on the basis of standard clinical criteria~* Capable of providing valid signed informed consent~* Normal middle-ear function as determined by tympanometry~* DPOAE meet criteria that are required for the research~* Acoustic stapedial reflex meets criteria that are required for the research~* Subject is willing and able to return for the study~Exclusion Criteria:~* Subject is pregnant~* Subject lacks decision-making capacity~* Subject is unwilling or unable to return for the study~* Prior middle-ear disease or surgery, with the exception of tympanostomy tubes that have been removed and are healed~* Participating in the study would significantly delay or interfere with the subject's healthcare~* Subject has excess ear wax that cannot be removed safely and could potentially be pushed onto the ear drum by the insertion of the ear plugs needed for the testing~* The TMD or DPOAE do not respond to a change in posture from lying flat to standing up, which means that the anatomic connection between the inner ear and the CSF is absent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Hydrocephalus/Pseudotumor (Type: EXPERIMENTAL): Patients between the ages of 18-65 years with suspected hydrocephalus or idiopathic intracranial hypertension (IIH), also known as pseudotumor cerebri, who are recommended by their doctor based on standard clinical criteria to undergo intracranial pressure monitoring. The interventions include tympanic membrane displacement (TMD) and DPOAE.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: The Effect of Sertindole and Risperidone on Endophenotypic Markers of Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Healthy controls:~* matched by age (+/- 2 years), gender and parental socioeconomic status to patients with schizophrenia.~* age between 18-55 years~* male~* physically and mentally healthy and no daily intake of medicine~* no current substance abuse~Patients:~* patients who fulfill both ICD-10 and DSM IV diagnostic criteria for schizophrenia.~* age between 18-55 years~* male~* patients who need a change in their medication~* diagnosed with schizophrenia within the last 10 years~* not formerly treated with risperidone (Risperdal) or sertindole (Serdolect) where treatment was stopped because of side effects or lack of effect~* physically healthy~* no current substance abuse~Exclusion Criteria:~Controls:~* a history of mental illness in the first degree relatives~* hearing disabilities~* head injury accompanied by unconsciousness for more than 5 min.~* physical illness with a need of daily intake of medicine~* positive screening for drugs of abuse at baseline.~Patients:~* head injury accompanied by unconsciousness for more than 5 min.~* serious medical conditions (more specific: brain diseases and diseases which cause a daily intake of medicine, heart, liver or kidney diseases, diabetes and prolongation of the QTc-interval (or a family history of such) and patients with phenylketonuri)~* abuse of alcohol or medication/ narcotics during the last 6 months or positive screening for drugs of abuse at baseline.~* former treatment with risperidone (Risperdal) or sertindole (Serdolect) where treatment was stopped because of side effects or lack of effect~* hearing disability~* allergy towards the content in the medicine used in the study~* bradycardia (pulse under 50 beats per minute) and QTc\>450 ms

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound
- 2 (Type: EXPERIMENTAL): Patients with schizophrenia will be treated with risperidone or sertindole for a period of 10 weeks, after which they will cross-over for an additional treatment of 10 weeks with the other compound

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate the Efficacy and Safety of Ocriplasmin in Inducing Total PVD in Subjects With NPDR

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female aged 18 years or older~* Best-corrected visual acuity (BCVA) of 65 letters read or greater (Snellen equivalent of 20/50 or better) in the study eye~* HbA1c ≤ 12%, as assessed by the central laboratory~* Moderate to very severe NPDR as per ETDRS Severity Scale, based on 7 standard field stereo colour fundus photograph~* Central subfield thickness of ≤ 340µm on Spectralis SD-OCT or ≤ 320µm on non-Spectralis SD OCT in the study eye, with or without mild centre-involved diabetic macular oedema~* No evidence of total PVD in the study eye~* Written informed consent obtained from the subject prior to screening procedures~Exclusion Criteria:~* History of or current ocular condition in the study eye that may interfere with the assessment of the progression to PDR~* Presence of epiretinal membrane in the study eye~* Presence of foveal ischemia in the study eye~* Presence of pre-retinal or vitreous haemorrhage in the study eye~* Presence of iris or angle neovascularisation in the study eye~* Any active ocular / intraocular infection or inflammation in either eye~* Aphakic study eye~* Uncontrolled hypertension in the opinion of the Investigator~* Pseudoexfoliation, Marfan's syndrome, phacodonesis or any other finding in the Investigator's opinion suggesting lens / zonular instability

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ocriplasmin 0.0625mg (Type: EXPERIMENTAL): None
- Ocriplasmin 0.125mg (Type: EXPERIMENTAL): None
- Sham injection (Type: SHAM_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Comparing the Efficacy of Visible Light-Ultraviolet A1 Light Versus Narrowband-Ultraviolet B on Generalized Vitiligo

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects ≥ 18 years of age with a diagnosis of generalized vitiligo~* Subjects on a stable topical/oral regimen for the past 3 months and continuing on a stable regimen~* Subjects able to understand the requirements of the study~* Subjects able and willing to sign informed consent~Exclusion Criteria:~* Subjects on photosensitizing medications~* Subjects receiving any concurrent phototherapy~* Subjects who plan to use tanning parlors or expose themselves to excess sunlight~* Subjects with known photosensitivity disorder~* Subjects with apparent phototoxicity~* Subjects with unstable vitiligo~* Subjects currently using bleaching agents~* Subjects who are pregnant, lactating, or planning on becoming pregnant~* Subjects who in the opinion of the investigator/sub-investigator, are not appropriate candidates for this study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- VL-UVA1 vs NB-UVB (Type: OTHER): Participants will be treated with both VL-UVA and NB-UVB on different areas

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: PET/MRI Perfusion and CT Perfusion in Solid Tumors

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* indication as stated above~* written informed consent~* patients with suspected or confirmed solid malignant tumors of the neck, chest or abdomen who have an indication for a PET/CT~Exclusion Criteria:~* pregnant or breast feeding women~* non compliance of the patient to follow the study instructions (e.g. hearing problems, dementia)~* Inclusion in another clinical trial 30 days prior to inclusion~* age \< 30years~* contraindication for MRI (cardiac pacemaker, certain metal implants, claustrophobia~* known allergies to contrast CT or MRI contrast media~* patients with an glomerular filtration rate of \< 60ml/min/1.73m2

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: EUS FNB Versus FNA With On-Site Cytopathology in Solid Pancreatic Masses

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: DOUBLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient ≥ 18 years of age referred for EUS-guided biopsy for pancreatic mass lesions~Exclusion Criteria:~* Refusal to consent form~* Uncorrectable coagulopathy (INR \> 1.5)~* Uncorrectable thrombocytopenia (platelet \< 50,000)~* Uncooperative patients~* Pregnant women (women of childbearing age will undergo urine pregnancy testing, which is routine for all endoscopic procedures)~* Medically unstable for sedation~* Entirely cystic lesions~* Lesions inaccessible to EUS

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EUS-FNA with ROSE (Type: ACTIVE_COMPARATOR): EUS/FNA with ROSE will be performed using standard techniques via 22-g FNA needle (Cook Medical EchoTip Ultra or Boston Scientific Expect or Medtronic Beacon). Lesions will be identified using EUS and punctured with the FNA needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNA specimens will be processed for ROSE using standard techniques with bedside smear slide evaluation and liquid-based cytology and cell-block preparation.
- EUS-FNB without ROSE (Type: ACTIVE_COMPARATOR): EUS/FNB without ROSE will be performed using similar techniques for tissue acquisition as FNA using 22-g FNB needle (Medtronic SharkCore or Boston Scientific Acquire). Lesions will be identified using EUS and punctured with the 22-g FNB needle (10-15 back and forth movements per needle pass, fanning as appropriate). After the lesion is punctured, the stylet will be removed and 10cc suction will be applied. FNB samples will be placed directly into formalin containers and sent to be processed by surgical pathology.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility
Please assess the completion status of the following clinical trial:

Trial Title: Intraoperative Pleth Variability Index (PVI) Variability

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Neurosurgical patients for tumor resection~* neurointerventional patients~* general anesthesia with mechanical ventilation~* communicates in english (consent)~* over 18 years of age~Exclusion Criteria:~* unable to sign consent~* less than 18 years of age

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- neurosurgical patients (Type: None): Neurosurgical patients undergoing craniotomies for tumor. 25 subjects
- Neurointerventional patients (Type: None): Patients undergoing neurointerventional procedures under general anesthesia. 25 subjects

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking Tamoxifen

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~i. Women age 18 years and older with localized breast cancer. Histologic documentation of atypical ductal hyperplasia, ductal carcinoma in situ (DCIS), lobular carcinoma in situ (LCIS), or invasive adenocarcinoma of the breast stages I-III A.~ii. Current daily tamoxifen use (≥ 6 days/week). Any planned surgery, adjuvant chemotherapy or radiation must have been completed.~iii. History of bothersome hot flushes: ≥ 14 hot flushes/week (average ≥ 2 hot flushes/day), sufficiently severe that intervention is desired. Participants must have had bothersome hot flushes for at least one month prior to enrollment.~Exclusion Criteria:~i. Women who is pregnant or breast feeding, or who has a history of seizure disorder or hepatic or renal insufficiency ii. Concurrent systemic hormone replacement therapy (estrogen, progestational agents, androgens) or use of corticosteroids iii. Concurrent use of other antidepressants, anxiolytics and antipsychotics, gabapentin, pregabalin and clonidine for treatment of hot flushes or depression.~iv. Presense or past history of severe psychiatric symptoms such as hallucinations and delusions, manic episodes, or high suicide risk.

- Gender: FEMALE
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desvenlafaxine succinate 100mg (Type: EXPERIMENTAL): Titration with 50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 2 tablets of 50mg Desvenlafaxine succinate tablet once daily for 3 weeks, then taper with 50 mg Desvenlafaxine succinate tablet once daily for 3 days.
- Desvenlafaxine succinate 50mg (Type: EXPERIMENTAL): 50 mg Desvenlafaxine succinate tablet once daily for 1 week, then 1 tablets of 50mg Desvenlafaxine succinate tablet and 1 tablet of 50mg placebo tablet once daily for 3 weeks, then 50mg placebo tablet once daily for 3 days.
- Placebo (Type: PLACEBO_COMPARATOR): 50 mg placebo tablet once daily for 1 week, then 2 tablets of 50mg placebo tablet once daily for 3 weeks, then 50 mg placebo tablet once daily for 3 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues
Please assess the completion status of the following clinical trial:

Trial Title: Dose Tapering Study of Adalimumab in Psoriasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Participants must have a clinical or histological diagnosis of chronic plaque-type psoriasis for at least 6 months prior to inclusion~2. Participants must have a stable disease during maintenance on adalimumab (absolute PASI \< 3)~3. Participants are not allowed to use topical steroids from 7 days before randomization until the end of the study (week 48).~4. Participants must sign an ICF indicating that he or she understands the purpose of, and procedures required for, the study and is willing to participate in the study~Exclusion Criteria:~1. Participants who have currently a predominant nonplaque form of psoriasis~2. Participants who are pregnant, nursing or planning a pregnancy while enrolled in the study or within 12 weeks after receiving the last administration of study intervention~3. Participants who are unable or unwilling to undergo multiple venapunctures~4. Participants who are treated according to a different dosing schedule than standard dosing of adalimumab (regular dose regimen every 2 weeks; 40 mg)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard dosing group (Type: ACTIVE_COMPARATOR): Patients will continue to receive adalimumab according to the standard dosing schedule.
- Dose tapering group (Type: EXPERIMENTAL): Adalimumab dosing frequency will be lowered in patients who have supratherapeutic serum trough levels of adalimumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues